Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

Craig H. Moskowitz, MD, Auayporn Nadamanee, MD, Tamas Masszi, MD PhD, Edward Agura, MD, Jerzy Holowiecki, MD PhD, Muneer H. Abidi, MD, Andy I Chen, MDPhD, Patrick J. Stiff, MD, Alessandro M. Gianni, MD, Angelo M. Carella, MD, Dzhelil Osmanov, MD, Veronika Bachanova, MD, John Sweetenham, MD, Anna Sureda, Dirk Huebner, MD, Emily K. Larsen, MS, Naomi N.H. Hunder, MD, Jan Walewski

Blood (2014) 124 (21): 673.

https://doi.org/10.1182/blood.V124.21.673.673

Published: 2014

Journal Articles

Minimal Residual Disease After the First Cycle of Chemotherapy in Acute Myeloid Leukemia: A Comparative Study of WT1 RQ-PCR and 4-Color Flow Cytometry.

Carlo Marani, MD, Raffaella Grasso, PhD, Nicoletta Colombo, Marino Clavio, MD, Fabio Guolo, MD, Annalisa Kunkl, Livia Giannoni, MD, Giuseppina Fugazza, PhD, Roberto Bruzzone, Mario Sessarego, MD, A. M. Carella, MD, Marco Gobbi, MD, Maurizio Miglino, PhD

Blood (2012) 120 (21): 2535.

https://doi.org/10.1182/blood.V120.21.2535.2535

Published: 2012

Journal Articles

Clarithromycin Enhances tyrosine Kinase Inhibitor – Induced Cell Death by Inhibition of Late Stage Autophagy in Patients with Chronic Myeloid Leukemia At Diagnosis or with Resistant Stage of Disease

A. M. Carella, MD, G. Beltrami, MD, G. Pica, MD, C. Ghiggi, MD, D. Lovera, MD, G. Cirmena, A. Garuti

Blood (2012) 120 (21): 3777.

https://doi.org/10.1182/blood.V120.21.3777.3777

Published: 2012

Journal Articles

Safety and Efficacy of 90Y Ibritumomab Tiuxetan (Zevalin®) for Untreated FollicularNon-Hodgkin's Lymphoma (FL) Patients, An Italian Cooperative Study

G. Pica, S. Nati, Umberto Vitolo, MD, Sara Galimberti, Pier Luigi Zinzani, MD, PhD, Nicola Cascavilla, Mario Petrini, MD, A. M. Carella, MD

Blood (2011) 118 (21): 100.

https://doi.org/10.1182/blood.V118.21.100.100

Published: 2011

Journal Articles

Clarithromycin Targeting Autophagy Potentiates Tyrosine Kinase Inhibitor-Induced Cell Death in Resistant Chronic Myeloid Leukemia (CML) Patients

A. M. Carella, MD, Gioacchino Catania, MD, G. Beltrami, G. Pica

Blood (2011) 118 (21): 4450.

https://doi.org/10.1182/blood.V118.21.4450.4450

Published: 2011

Journal Articles

GeneXpert Essay for BCR-ABL Compared to RT-PCR for Clinical Management of CML

G. Pica, G. Catania, F. Castelli, C Repetto, A. M. Carella, MD, M. Mussap

Blood (2011) 118 (21): 4416.

https://doi.org/10.1182/blood.V118.21.4416.4416

Published: 2011

Journal Articles

A Phase I Study of Hypofractionated Tailored Total Marrow or Total Lymphoid Irradiation with Helical Tomotherapy Plus Chemotherapy As a Conditioning Regimen for Autologous Stem Cell Transplantation

G. Pica, S. Vagge, G. Beltrami, S. Nati, G. Catania, R. Corvò, A. M. Carella, MD

Blood (2011) 118 (21): 4523.

https://doi.org/10.1182/blood.V118.21.4523.4523

Published: 2011

Journal Articles

Non-Pegylated Lyposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone and Rituximab (R-COMP) as Initial Treatment for Patients with Splenic Marginal Zone Lymphoma (SMZL). A GISL Study

Emilio Iannitto, MD, Stefano Luminari, MD, Caterina Mammi, MD, Viviana Minardi, Francesco Merli, MD, Francesco Angrilli, MD, Caterina Stelitano, MD, Marina Cesaretti, Giovanni Franco, MD, Angelo M. Carella, MD, Massimo Federico, MD

Blood (2007) 110 (11): 1293.

https://doi.org/10.1182/blood.V110.11.1293.1293

Published: 2007

Journal Articles

Autologous Stem Cell Transplantation Followed by Reduced Intensity Allogeneic Stem Cell Transplantation (Tandem Transplantation) as Treatment for Advanced Resistant Hodgkin’s Lymphoma Patients. A Retrospective Analysis of the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT).

Ivan Alvarez, MD, Carme Canals, MD, Goli Taghipour, Angelo M. Carella, MD, PhD, Yves Beguin, MD, PhD, Didier Blaise, MD, PhD, Danielle Lazzlo, MD, PhD, Bernardino Aillone, MD, PhD, Jean H. Bourhis, MD, PhD, Lucca Castagna, MD, PhD, Paolo Corradini, MD, PhD, Paolo Iacopino, MD, PhD, Giuseppe Milone, MD, PhD, Pedro Pimentel, MD, PhD, Nigel H. Russell, MD, PhD, Pierre Zachee, MD, PhD, Anna Sureda, MD, PhD

Blood (2006) 108 (11): 3044.

https://doi.org/10.1182/blood.V108.11.3044.3044

Published: 2006

Journal Articles

Control of Residual Disease in Imatinib Treated Chronic Myeloid Leukemia Patients with Peptide Vaccinations: 2 Years Follow up of CMLVAX100 Trial.

Monica Bocchia, MD, Elisabetta Abruzzese, MD, Micaela Ippoliti, PhD, Maria Teresa Pirrotta, MD, Malgorzata M. Trawinska, MD, Marilina Amabile, PhD, Giovanni Martinelli, MD, Francesco Forconi, MD, Alessandro Gozzetti, MD, Angelo M. Carella, MD, Donatella Raspadori, PhD, Francesco Lauria, MD

Blood (2005) 106 (11): 167.

https://doi.org/10.1182/blood.V106.11.167.167

Published: 2005

Journal Articles

Autografting Followed Closely by Nonmyeloablative Allografting as Consolidation Immunotherapy Reduces Disease Progression Compared to Tandem Autografting in Multiple Myeloma.

A.M. Carella, MD, M. Spriano, MD, M. T. Corsetti, MD, P. Scalzulli, MD, G. Beltrami, MD, E. Lerma, MD, PhD, N. Cascavilla, MD, M. Carella, MD, S. Nati, MD, A. Congiu, MD, P. Musto, MD

Blood (2005) 106 (11): 1126.

https://doi.org/10.1182/blood.V106.11.1126.1126

Published: 2005

NARROW

The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

Minimal Residual Disease After the First Cycle of Chemotherapy in Acute Myeloid Leukemia: A Comparative Study of WT1 RQ-PCR and 4-Color Flow Cytometry.

Clarithromycin Enhances tyrosine Kinase Inhibitor – Induced Cell Death by Inhibition of Late Stage Autophagy in Patients with Chronic Myeloid Leukemia At Diagnosis or with Resistant Stage of Disease

Safety and Efficacy of 90Y Ibritumomab Tiuxetan (Zevalin®) for Untreated FollicularNon-Hodgkin's Lymphoma (FL) Patients, An Italian Cooperative Study

Clarithromycin Targeting Autophagy Potentiates Tyrosine Kinase Inhibitor-Induced Cell Death in Resistant Chronic Myeloid Leukemia (CML) Patients

GeneXpert Essay for BCR-ABL Compared to RT-PCR for Clinical Management of CML

A Phase I Study of Hypofractionated Tailored Total Marrow or Total Lymphoid Irradiation with Helical Tomotherapy Plus Chemotherapy As a Conditioning Regimen for Autologous Stem Cell Transplantation

Non-Pegylated Lyposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone and Rituximab (R-COMP) as Initial Treatment for Patients with Splenic Marginal Zone Lymphoma (SMZL). A GISL Study

Control of Residual Disease in Imatinib Treated Chronic Myeloid Leukemia Patients with Peptide Vaccinations: 2 Years Follow up of CMLVAX100 Trial.

Autografting Followed Closely by Nonmyeloablative Allografting as Consolidation Immunotherapy Reduces Disease Progression Compared to Tandem Autografting in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only